Concourse Financial Group Securities, Inc. Biotechnology

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NBTX Nanobiotix S.A.	$302M	$0 100.0% of portfolio	0	Q2 2025 New
NAUT Nautilus Biotechnology, Inc.	$84.8M	$0 100.0% of portfolio	0	Q2 2025 New
NRSN Neuro Sense Therapeutics Ltd.	$12.4M	$0 100.0% of portfolio	0	Q2 2025 New
NXTC Next Cure, Inc.	$135M	$0 100.0% of portfolio	0	Q2 2025 New
NKTX Nkarta, Inc.	$103M	$0 100.0% of portfolio	0	Q2 2025 New
NVAX Novavax Inc	$591M	$0 100.0% of portfolio	0	Q2 2025 New
NVO Novo Nordisk A S	$127B	$0 100.0% of portfolio	0	Q2 2025 New
NRXPW Nrx Pharmaceuticals Inc Wt Exp	$0	$0 100.0% of portfolio	0	Q2 2025 New
NRIX Nurix Therapeutics, Inc.	$440M	$0 100.0% of portfolio	0	Q2 2025 New
NTRB Nutri Band Inc.	$46.7M	$0 100.0% of portfolio	0	Q2 2025 New
NUVL Nuvalent, Inc.	$3.29B	$0 100.0% of portfolio	0	Q2 2025 New
NUVB Nuvation Bio Inc.	$645M	$0 100.0% of portfolio	0	Q2 2025 New
NVCT Nuvectis Pharma, Inc.	$93.4M	$0 100.0% of portfolio	0	Q2 2025 New
OBSV Obs Eva Sa	$0	$0 100.0% of portfolio	0	Q2 2025 New
OCGN Ocugen, Inc.	$221M	$0 100.0% of portfolio	0	Q2 2025 New
OCUL Ocular Therapeutix, Inc	$940M	$0 100.0% of portfolio	0	Q2 2025 New
OCUP Ocuphire Pharma, Inc.	$20.2M	$0 100.0% of portfolio	0	Q2 2025 New
OLMA Olema Pharmaceuticals, Inc.	$226M	$0 100.0% of portfolio	0	Q2 2025 New
OMER Omeros Corp	$261M	$0 100.0% of portfolio	0	Q2 2025 New
ONCY Oncolytics Biotech Inc	$64.2M	$0 100.0% of portfolio	0	Q2 2025 New
OPNT Opiant Pharmaceuticals, Inc.	$0	$0 100.0% of portfolio	0	Q2 2025 New
OGEN Oragenics Inc	$120M	$0 100.0% of portfolio	0	Q2 2025 New
ORMP Oramed Pharmaceuticals Inc.	$83.1M	$0 100.0% of portfolio	0	Q2 2025 New
ORTX Orchard Therapeutics PLC	$0	$0 100.0% of portfolio	0	Q2 2025 New
ORIC Oric Pharmaceuticals, Inc.	$412M	$0 100.0% of portfolio	0	Q2 2025 New
OVID Ovid Therapeutics Inc.	$88M	$0 100.0% of portfolio	0	Q2 2025 New
OYST Oyster Point Pharma, Inc.	$0	$0 100.0% of portfolio	0	Q2 2025 New
PBLA Panbela Therapeutics, Inc.	$3.12M	$0 100.0% of portfolio	0	Q2 2025 New
KTTAW Pasithea Therapeutics Corp Wt	$0	$0 100.0% of portfolio	0	Q2 2025 New
PASG Passage Bio, Inc.	$383M	$0 100.0% of portfolio	0	Q2 2025 New
PDSB Pds Biotechnology Corp	$35.9M	$0 100.0% of portfolio	0	Q2 2025 New
PEPG Pep Gen Inc.	$28.4M	$0 100.0% of portfolio	0	Q2 2025 New
PMCB Pharma Cyte Biotech, Inc.	$19.9M	$0 100.0% of portfolio	0	Q2 2025 New
PHAR Pharming Group N.V.	$972M	$0 100.0% of portfolio	0	Q2 2025 New
PHVS Pharvaris N.V.	$731M	$0 100.0% of portfolio	0	Q2 2025 New
PHAT Phathom Pharmaceuticals, Inc.	$477M	$0 100.0% of portfolio	0	Q2 2025 New
PHIO Phio Pharmaceuticals Corp.	$27.5M	$0 100.0% of portfolio	0	Q2 2025 New
PLRX Pliant Therapeutics, Inc.	$79.8M	$0 100.0% of portfolio	0	Q2 2025 New
PMVP Pmv Pharmaceuticals, Inc.	$63.9M	$0 100.0% of portfolio	0	Q2 2025 New
PGEN Precigen, Inc.	$939M	$0 100.0% of portfolio	0	Q2 2025 New
PRLD Prelude Therapeutics Inc	$44M	$0 100.0% of portfolio	0	Q2 2025 New
PROK Prokidney Corp Ord Shs Cl A(Cy	$145M	$0 100.0% of portfolio	0	Q2 2025 New
PRQR Pro Qr Therapeutics N.V.	$161M	$0 100.0% of portfolio	0	Q2 2025 New
PTIX Protagenic Therapeutics, Inc.New	$61.8M	$0 100.0% of portfolio	0	Q2 2025 New
PTGX Protagonist Therapeutics, Inc	$2.9B	$0 100.0% of portfolio	0	Q2 2025 New
PLX Protalix Bio Therapeutics, Inc.	$82.1M	$0 100.0% of portfolio	0	Q2 2025 New
TARA Protara Therapeutics, Inc.	$35.5M	$0 100.0% of portfolio	0	Q2 2025 New
PRTA Prothena Corp Public LTD CO	$388M	$0 100.0% of portfolio	0	Q2 2025 New
PTCT Ptc Therapeutics, Inc.	$3.75B	$0 100.0% of portfolio	0	Q2 2025 New
PBYI Puma Biotechnology, Inc.	$233M	$0 100.0% of portfolio	0	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.